about
Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular DystrophyLaminin and alpha7beta1 integrin regulate agrin-induced clustering of acetylcholine receptorsLocalization of the human indoleamine 2,3-dioxygenase (IDO) gene to the pericentromeric region of human chromosome 8The gene for the serpin thrombin inhibitor (PI7), protease nexin I, is located on human chromosome 2q33-q35 and on syntenic regions in the mouse and sheep genomesRole for the alpha7beta1 integrin in vascular development and integrityThe alpha7beta1 integrin in muscle development and disease.Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy.Cardiac-specific, inducible ClC-3 gene deletion eliminates native volume-sensitive chloride channels and produces myocardial hypertrophy in adult miceThe muscle integrin binding protein (MIBP) interacts with alpha7beta1 integrin and regulates cell adhesion and laminin matrix deposition.Mapping, sequence, and expression analysis of the human fertilin beta gene (FTNB).Sarcospan integration into laminin-binding adhesion complexes that ameliorate muscular dystrophy requires utrophin and α7 integrin.Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice.Bit-1 is an essential regulator of myogenic differentiation.Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophyPlacental defects in alpha7 integrin null miceA functional role for specific spliced variants of the alpha7beta1 integrin in acetylcholine receptor clustering.Dystrophin and utrophin expression require sarcospan: loss of α7 integrin exacerbates a newly discovered muscle phenotype in sarcospan-null mice.Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic miceSheep CENPB and CENPC genes show a high level of sequence similarity and conserved synteny with their human homologs.Isolation of chromosome-specific paints from high-resolution flow karyotypes of the sheep (Ovis aries).Heart-specific overexpression of the human short CLC-3 chloride channel isoform limits myocardial ischemia-induced ERP and QT prolongation.Exercise promotes alpha7 integrin gene transcription and protection of skeletal muscleIncreasing alpha 7 beta 1-integrin promotes muscle cell proliferation, adhesion, and resistance to apoptosis without changing gene expression.Activation of volume regulated chloride channels protects myocardium from ischemia/reperfusion damage in second-window ischemic preconditioning.Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathyLevels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy.Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy.Alpha 7 integrin preserves the function of the extensor digitorum longus muscle in dystrophin-null mice.Report on the Myomatrix Conference April 22-24, 2012, University of Nevada, Reno, Nevada, USAUse of the Indian muntjac idiogram to align conserved chromosomal segments in sheep and human genomes by chromosome painting.Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy.PTRH2 gene mutation causes progressive congenital skeletal muscle pathology.Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.Activation of AKT signaling promotes cell growth and survival in α7β1 integrin-mediated alleviation of muscular dystrophy.Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.ECM-Related Myopathies and Muscular Dystrophies: Pros and Cons of Protein Therapies.Alpha7beta1-integrin regulates mechanotransduction and prevents skeletal muscle injury.The chromosomal distribution and organization of sheep satellite I and II centromeric DNA using characterized sheep-hamster somatic cell hybrids.
P50
Q27318308-2c2dca6a-424e-37f7-4e7a-40a8e3341626Q28141768-3eaf34ce-4e12-07ea-7271-ee78b5c0050cQ28264519-4fd9a00b-482c-da04-ec4b-83c77a7f679aQ28296809-664D7CB2-FD69-4903-8E32-29AF53262270Q28504523-acbc13a3-44e1-4e07-3423-48fba60f8328Q33592124-b0acb119-40a4-ef3b-ab57-bbb0b3f9ecd2Q33787898-68f7ffa6-4196-99d7-59f6-48fde800d2f3Q33887679-9e5a9413-45f2-7384-561a-1c8d7a84ae2cQ34225519-e01002c0-42d8-df1e-389d-3d4e69dfc655Q34419647-28c9fd2a-49a5-8761-4216-8e9da38b04f0Q34453676-bce04ec9-4357-6f17-332e-0acafbf0a151Q35083511-c9cc7a6f-4c59-cc6a-053c-ed0935cd3ac5Q35657951-BB2BBD2E-147B-4308-909C-95285D595226Q35952091-7c959f79-416b-0279-adc5-37231da95738Q36248770-88471c6c-4792-1a56-b1fd-48d7ece5fc16Q36255897-07519fdb-4834-15b9-cd01-56becd340affQ36283349-016be13d-4dda-d9d6-9e43-1d05aa326699Q36381102-83d53928-4200-f7ab-69e0-9c16cda82261Q36829766-6134e5eb-4810-1d4a-a5dc-ab289e95986fQ36860127-2eaafeaf-4597-7874-5d61-cdaa95f78174Q36889256-8ad1bd27-4a0f-b1ff-d4f2-d978881fc6eeQ36977244-a25ed08b-4d1d-bc28-3613-62755bb8cfc2Q36995702-2c44913d-4759-7f92-3ab5-ff1d3f05ce2bQ37005240-DF31CC6E-BA5A-46A2-BF61-DD2DA6F35385Q37073808-dc32c5fa-487d-0924-7884-ba620795ff91Q37137768-27a3aa8f-4731-683c-330a-3decf24e8f46Q37150816-9dd6b09c-475b-4e19-1576-355bd521978cQ37194805-4800e6a9-4124-6afa-6c48-232f87149156Q37346142-a4ede3f0-4b32-c47a-31b2-06e4c39ee7e2Q37590105-18ACF1DC-F6B2-463D-B587-F1D8C44993E1Q38503598-b8be3811-43bb-1f97-6ebd-d081ea08c3a5Q38882098-431db0b9-4f34-888c-2995-2a03322943afQ38973118-7e4f1cfe-47a7-15ff-7c28-84f9b1737e15Q41881081-ba284ded-47d5-4672-4d02-37a04b38bf45Q42489627-66731106-45fa-acf7-b2a3-5d4257141ebdQ42639922-62ae44de-4eac-88ba-436f-83857e37ac1fQ45016329-537fb9d3-48c9-831a-1d2b-4b412cac6710Q45871995-07907ba7-4c3e-9978-5ad3-8ce1612e25cdQ46900053-b627dc99-4c60-2ac7-fd9b-ad4a5a5831e1Q47187773-04a5988b-4abf-df69-771e-f020a7f0b080
P50
description
biomedical researcher
@en
onderzoeker
@nl
name
Dean Burkin
@ast
Dean Burkin
@en
Dean Burkin
@es
Dean Burkin
@nl
type
label
Dean Burkin
@ast
Dean Burkin
@en
Dean Burkin
@es
Dean Burkin
@nl
altLabel
Dean J Burkin
@en
Dean J. Burkin
@en
prefLabel
Dean Burkin
@ast
Dean Burkin
@en
Dean Burkin
@es
Dean Burkin
@nl
P69
P106
P1153
35253450600
P1960
aopw69YAAAAJ
P21
P2381
P2798
P31
P496
0000-0001-9228-5258